Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume -, Issue -, Pages 1-17
Publisher
Informa UK Limited
Online
2019-03-28
DOI
10.1080/13543776.2019.1597850
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
- (2018) Marian C. Bryan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Interleukin-1 receptor–associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling
- (2018) Dominic De Nardo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
- (2017) Katherine L. Lee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)
- (2016) W. Michael Seganish EXPERT OPINION ON THERAPEUTIC PATENTS
- Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury
- (2016) Irina A. Leaf et al. JOURNAL OF CLINICAL INVESTIGATION
- Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity
- (2016) Shailesh Dudhgaonkar et al. JOURNAL OF IMMUNOLOGY
- Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
- (2015) Priscilla N. Kelly et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4
- (2015) Jongwon Lim et al. ACS Medicinal Chemistry Letters
- Interleukin 1/Toll-like Receptor-induced Autophosphorylation Activates Interleukin 1 Receptor-associated Kinase 4 and Controls Cytokine Induction in a Cell Type-specific Manner
- (2014) Leah Cushing et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Recent Advances in the Discovery of Small Molecule Inhibitors of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) as a Therapeutic Target for Inflammation and Oncology Disorders
- (2014) Divya Chaudhary et al. JOURNAL OF MEDICINAL CHEMISTRY
- NF- B, an Active Player in Human Cancers
- (2014) Y. Xia et al. Cancer Immunology Research
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- The interleukin-1 receptor-associated kinases: Critical regulators of innate immune signalling
- (2010) Sinead Flannery et al. BIOCHEMICAL PHARMACOLOGY
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling
- (2010) Su-Chang Lin et al. NATURE
- The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation
- (2009) Magdalena Koziczak-Holbro et al. ARTHRITIS AND RHEUMATISM
- The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress
- (2009) Luke A. J. O'Neill IMMUNOLOGICAL REVIEWS
- An Oligomeric Signaling Platform Formed by the Toll-like Receptor Signal Transducers MyD88 and IRAK-4
- (2009) Precious G. Motshwene et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IRAK-4 kinase activity is required for IRAK-4-dependent innate and adaptive immune responses
- (2008) Elizabeth Lye et al. EUROPEAN JOURNAL OF IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started